AstraZeneca’s (AZN) Sell Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

AstraZeneca (LON:AZN)‘s stock had its “sell” rating reissued by Deutsche Bank Aktiengesellschaft in a research note issued on Thursday,London Stock Exchange reports. They currently have a £115 price target on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective indicates a potential downside of 17.56% from the company’s previous close.

A number of other research analysts have also weighed in on AZN. Jefferies Financial Group reissued a “buy” rating and set a £180 price target on shares of AstraZeneca in a research report on Wednesday, May 13th. Berenberg Bank increased their price objective on shares of AstraZeneca from £145 to £160 and gave the company a “buy” rating in a research note on Tuesday, January 27th. Finally, Citigroup lifted their target price on shares of AstraZeneca from £170 to £180 and gave the stock a “buy” rating in a research report on Friday, April 10th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, AstraZeneca has a consensus rating of “Moderate Buy” and an average price target of £153.33.

AstraZeneca Stock Performance

AZN remained flat at £139.50 during mid-day trading on Thursday. 41,023,766 shares of the company’s stock were exchanged, compared to its average volume of 34,744,191. AstraZeneca has a 1 year low of £101.03 and a 1 year high of £157.32. The company has a debt-to-equity ratio of 71.66, a current ratio of 0.91 and a quick ratio of 0.59. The stock has a market capitalization of £216.34 billion, a PE ratio of 21.01, a PEG ratio of 0.86 and a beta of 0.22. The business has a 50-day moving average of £143.13 and a 200 day moving average of £140.81.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.